Literature DB >> 25288089

KPC-producing Klebsiella pneumoniae strains that harbor AAC(6')-Ib exhibit intermediate resistance to amikacin.

Derek N Bremmer1, Cornelius J Clancy2, Ellen G Press3, Reem Almaghrabi3, Liang Chen4, Yohei Doi3, M Hong Nguyen5, Ryan K Shields6.   

Abstract

The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4× the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25288089      PMCID： PMC4249530          DOI： 10.1128/AAC.03831-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Aminoglycosides: activity and resistance.

Authors:  M P Mingeot-Leclercq; Y Glupczynski; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

Authors:  D M Livermore; S Mushtaq; M Warner; J-C Zhang; S Maharjan; M Doumith; N Woodford
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

3.  Prevalence of 16S rRNA methylase genes in Klebsiella pneumoniae isolates from a Chinese teaching hospital: coexistence of rmtB and armA genes in the same isolate.

Authors:  Fangyou Yu; Liangxing Wang; Jingye Pan; Dan Yao; Chan Chen; Tao Zhu; Qiang Lou; Jian Hu; Yang Wu; Xueqing Zhang; Zengqiang Chen; Di Qu
Journal:  Diagn Microbiol Infect Dis       Date:  2009-02-18       Impact factor: 2.803

4.  Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.

Authors:  Ricardo Gálvez; Cecilia Luengo; Rodrigo Cornejo; Johann Kosche; Carlos Romero; Eduardo Tobar; Victor Illanes; Osvaldo Llanos; José Castro
Journal:  Int J Antimicrob Agents       Date:  2011-05-25       Impact factor: 5.283

5.  In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae.

Authors:  Azza Elemam; Joseph Rahimian; Mehmet Doymaz
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

Review 6.  Aminoglycoside modifying enzymes.

Authors:  Maria S Ramirez; Marcelo E Tolmasky
Journal:  Drug Resist Updat       Date:  2010-09-15       Impact factor: 18.500

7.  Isolation, characterization, and cloning of a plasmid-borne gene encoding a phosphotransferase that confers high-level amikacin resistance in enteric bacilli.

Authors:  R Gaynes; E Groisman; E Nelson; M Casadaban; S A Lerner
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

8.  Aminoglycoside resistance in clinical Escherichia coli and Klebsiella pneumoniae isolates from Western Norway.

Authors:  Paul Christoffer Lindemann; Kine Risberg; Harald G Wiker; Haima Mylvaganam
Journal:  APMIS       Date:  2011-12-19       Impact factor: 3.205

9.  Appearance of amikacin and tobramycin resistance due to 4'-aminoglycoside nucleotidyltransferase [ANT(4')-II] in gram-negative pathogens.

Authors:  G A Jacoby; M J Blaser; P Santanam; H Hächler; F H Kayser; R S Hare; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

10.  Aminoglycoside susceptibility profiles of Enterobacter cloacae isolates harboring the aac(6')-Ib gene.

Authors:  Soo-Young Kim; Yeon-Joon Park; Jin Kyung Yu; Yeong Sic Kim
Journal:  Korean J Lab Med       Date:  2011-10-03
View more
  9 in total

1.  Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series.

Authors:  Rita Murri; Barbara Fiori; Teresa Spanu; Ilaria Mastrorosa; Francesca Giovannenze; Francesco Taccari; Claudia Palazzolo; Giancarlo Scoppettuolo; Giulio Ventura; Maurizio Sanguinetti; Roberto Cauda; Massimo Fantoni
Journal:  Infection       Date:  2017-02-09       Impact factor: 3.553

2.  Correlation of Checkerboard Synergy Testing with Time-Kill Analysis and Clinical Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Respiratory Infections.

Authors:  Derek N Bremmer; Karri A Bauer; Stephanie M Pouch; Keelie Thomas; Debra Smith; Debra A Goff; Preeti Pancholi; Joan-Miquel Balada-Llasat
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

3.  Risk factors and mortality in the Carbapenem-resistant Klebsiella pneumoniae infection: case control study.

Authors:  Fethiye Akgul; Ilkay Bozkurt; Mustafa Sunbul; Saban Esen; Hakan Leblebicioglu
Journal:  Pathog Glob Health       Date:  2016-12-01       Impact factor: 2.894

4.  Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae.

Authors:  Yanqin Huang; Amisha P Rana; Eric Wenzler; Egon A Ozer; Fiorella Krapp; Jürgen B Bulitta; Alan R Hauser; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2022-02-02       Impact factor: 5.758

5.  Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum β-Lactamases Collected in Two Multicenter Studies in Spain.

Authors:  Marta Fernández-Martínez; Belén Ruiz Del Castillo; Maria Jesús Lecea-Cuello; Jesús Rodríguez-Baño; Álvaro Pascual; Luis Martínez-Martínez
Journal:  Microb Drug Resist       Date:  2017-10-03       Impact factor: 3.431

6.  Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.

Authors:  Ghady Haidar; Ammar Alkroud; Shaoji Cheng; Travis M Churilla; Bryce M Churilla; Ryan K Shields; Yohei Doi; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

7.  Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (AME) gene aac(6')-Ib.

Authors:  David A Butler; Amisha P Rana; Fiorella Krapp; Shitalben R Patel; Yanqin Huang; Egon A Ozer; Alan R Hauser; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

8.  Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae.

Authors:  Yanqin Huang; Karol Sokolowski; Amisha Rana; Nidhi Singh; Jiping Wang; Ke Chen; Yinzhi Lang; Jieqiang Zhou; Neera Kadiyala; Fiorella Krapp; Egon A Ozer; Alan R Hauser; Jian Li; Jürgen B Bulitta; Zackery P Bulman
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

9.  Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.

Authors:  M Thwaites; D Hall; D Shinabarger; A W Serio; K M Krause; A Marra; C Pillar
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.